Force of infection: a determinant of vaccine efficacy?

Abstract Vaccine efficacy (VE) can vary in different settings. Of the many proposed setting-dependent determinants of VE, force of infection (FoI) stands out as one of the most direct, proximate, and actionable. As highlighted by the COVID-19 pandemic, modifying FoI through non-pharmaceutical interv...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: David C. Kaslow
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/66616f8e1eff4f78914611366ca5864a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:66616f8e1eff4f78914611366ca5864a
record_format dspace
spelling oai:doaj.org-article:66616f8e1eff4f78914611366ca5864a2021-12-02T14:30:51ZForce of infection: a determinant of vaccine efficacy?10.1038/s41541-021-00316-52059-0105https://doaj.org/article/66616f8e1eff4f78914611366ca5864a2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00316-5https://doaj.org/toc/2059-0105Abstract Vaccine efficacy (VE) can vary in different settings. Of the many proposed setting-dependent determinants of VE, force of infection (FoI) stands out as one of the most direct, proximate, and actionable. As highlighted by the COVID-19 pandemic, modifying FoI through non-pharmaceutical interventions (NPIs) use can significantly contribute to controlling transmission and reducing disease incidence and severity absent highly effective pharmaceutical interventions, such as vaccines. Given that NPIs reduce the FoI, the question arises as to if and to what degree FoI, and by extension NPIs, can modify VE, and more practically, as vaccines become available for a pathogen, whether and which NPIs should continue to be used in conjunction with vaccines to optimize controlling transmission and reducing disease incidence and severity.David C. KaslowNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-7 (2021)
institution DOAJ
collection DOAJ
language EN
topic Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
David C. Kaslow
Force of infection: a determinant of vaccine efficacy?
description Abstract Vaccine efficacy (VE) can vary in different settings. Of the many proposed setting-dependent determinants of VE, force of infection (FoI) stands out as one of the most direct, proximate, and actionable. As highlighted by the COVID-19 pandemic, modifying FoI through non-pharmaceutical interventions (NPIs) use can significantly contribute to controlling transmission and reducing disease incidence and severity absent highly effective pharmaceutical interventions, such as vaccines. Given that NPIs reduce the FoI, the question arises as to if and to what degree FoI, and by extension NPIs, can modify VE, and more practically, as vaccines become available for a pathogen, whether and which NPIs should continue to be used in conjunction with vaccines to optimize controlling transmission and reducing disease incidence and severity.
format article
author David C. Kaslow
author_facet David C. Kaslow
author_sort David C. Kaslow
title Force of infection: a determinant of vaccine efficacy?
title_short Force of infection: a determinant of vaccine efficacy?
title_full Force of infection: a determinant of vaccine efficacy?
title_fullStr Force of infection: a determinant of vaccine efficacy?
title_full_unstemmed Force of infection: a determinant of vaccine efficacy?
title_sort force of infection: a determinant of vaccine efficacy?
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/66616f8e1eff4f78914611366ca5864a
work_keys_str_mv AT davidckaslow forceofinfectionadeterminantofvaccineefficacy
_version_ 1718391194661158912